Kanabo, one of Europe’s fastest-growing medical cannabis companies, today announced that its unique CBD and nicotine formula has moved from Patent Cooperation Treaty (PCT) phase to National Phase in the US, the UK, and EU countries – the last phase before becoming an internationally approved patent.
According to a press release sent to Canex, the formula is targeted at people wanting to quit both traditional smoking and their e-cigarettes is a huge market that is expected to reach £50m within a few years.
Kanabo’s unique, high potency CBD and nicotine, and standalone CBD formulas – delivered by their proprietary cartridges and VapePod – can be used to treat nicotine and tobacco addiction. So far, evidence suggests the product could significantly reduce physical and psychological nicotine withdrawal effects.
Covered under the Kanabo patent application is the unique new formula development of specific naturally derived terpenes to allow the application of a very consistent and reproducible, high concentration of CBD throughout the life of the Kanabo cartridge.
Initially, CBD is combined with nicotine, which is then reduced over several weeks until there is zero nicotine presence
A handful of volunteers who smoke, that participated in Kanabo’s trial, have presented an average reduction of 70 per cent in their cigarette consumption. It was also reported that they did not experience physical or psychological withdrawal effects.
Avihu Tamir, CEO Kanabo, said: “Our unique patent-pending CBD formulations and controlled and consistent delivery device, the VapePod, represents an excellent opportunity for governments to quickly end the reliance on tobacco for millions of citizens worldwide.
“Our tests show a dramatic reduction in nicotine consumption, whether in cigarettes or e-cigarettes, which can only be good news for health services around the world.”